Search Results - "Curry, Michael P"

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome by Wong, Florence, Pappas, S. Chris, Curry, Michael P, Reddy, K. Rajender, Rubin, Raymond A, Porayko, Michael K, Gonzalez, Stevan A, Mumtaz, Khalid, Lim, Nicholas, Simonetto, Douglas A, Sharma, Pratima, Sanyal, Arun J, Mayo, Marlyn J, Frederick, R. Todd, Escalante, Shannon, Jamil, Khurram

“…In a phase 3 randomized trial, 199 patients with type 1 hepatorenal syndrome were assigned to receive the vasoconstrictor terlipressin plus albumin and 101 to…”
Get full text

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation by Charlton, Michael, Gane, Edward, Manns, Michael P, Brown, Robert S, Curry, Michael P, Kwo, Paul Y, Fontana, Robert J, Gilroy, Richard, Teperman, Lewis, Muir, Andrew J, McHutchison, John G, Symonds, William T, Brainard, Diana, Kirby, Brian, Dvory-Sobol, Hadas, Denning, Jill, Arterburn, Sarah, Samuel, Didier, Forns, Xavier, Terrault, Norah A

“…Background & Aims Interferon alfa–based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated,…”
Get full text

Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study by Curry, Michael P, Forns, Xavier, Chung, Raymond T, Terrault, Norah A, Brown, Robert, Fenkel, Jonathan M, Gordon, Fredric, O’Leary, Jacqueline, Kuo, Alexander, Schiano, Thomas, Everson, Gregory, Schiff, Eugene, Befeler, Alex, Gane, Edward, Saab, Sammy, McHutchison, John G, Subramanian, G. Mani, Symonds, William T, Denning, Jill, McNair, Lindsay, Arterburn, Sarah, Svarovskaia, Evguenia, Moonka, Dilip, Afdhal, Nezam

“…Background & Aims Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection…”
Get full text

Liver transplantation in alcohol-associated liver disease: ensuring equity through new processes by Messinger, John C, Hanto, Douglas W, Curry, Michael P, Ladin, Keren

“…Worsened by the COVID-19 pandemic, alcohol use is one of the leading causes of preventable death in the US, in large part due to alcohol-associated liver…”
Get full text

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection by Lin, Ming V, Sise, Meghan E, Pavlakis, Martha, Amundsen, Beth M, Chute, Donald, Rutherford, Anna E, Chung, Raymond T, Curry, Michael P, Hanifi, Jasmine M, Gabardi, Steve, Chandraker, Anil, Heher, Eliot C, Elias, Nahel, Riella, Leonardo V

“…The prevalence of Hepatitis C Virus (HCV) infection is significantly higher in patients with end-stage renal disease compared to the general population and…”
Get full text

International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates by Terrault, Norah A, McCaughan, Geoff W, Curry, Michael P, Gane, Edward, Fagiuoli, Stefano, Fung, James Y Y, Agarwal, Kosh, Lilly, Les, Strasser, Simone I, Brown, Kimberly A, Gadano, Adrian, Kwo, Paul Y, Burra, Patrizia, Samuel, Didier, Charlton, Michael, Pessoa, Mario G, Berenguer, Marina

Get full text

Risk factors and outcomes associated with alcohol relapse after liver transplantation by Lim, Jane, Curry, Michael P, Sundaram, Vinay

“…Alcoholic liver disease(ALD) is the second most common indication for liver transplantation(LT) in the United States and Europe. Unlike other indications for…”
Get full text

Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c by Trivedi, Hirsh D., Tran, Qua, Fricker, Zachary, Curry, Michael P., Li, Jonathan X., Lai, Michelle

“…The association between type 2 diabetes, non-alcoholic fatty liver disease, and liver fibrosis is well established, but it is unknown whether complications of…”
Get full text

Evidence of bias during liver transplant evaluation of non‐alcoholic steatohepatitis cirrhosis patients by Danford, Christopher J., Iriana, Sentia, Shen, Changyu, Curry, Michael P., Lai, Michelle

“…Background & Aims Cardiovascular disease (CVD) is the leading cause of death among non‐alcoholic steatohepatitis (NASH) patients and a major source of…”
Get full text

Reply to: The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population by Trivedi, Hirsh D., Curry, Michael P., Lai, Michelle

Get full text

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies by Curry, Michael P, Vargas, Hugo E, Befeler, Alex S, Pyrsopoulos, Nikolaos T, Patwardhan, Vilas R, Jamil, Khurram

“…Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated…”
Get full text

Neurologic Manifestations of Hepatitis C Virus Infection by Iriana, Sentia, MD, Curry, Michael P., MD, Afdhal, Nezam H., MD, DSc

“…The extrahepatic manifestations of hepatitis C include effects on the central nervous system, which have been associated with the ability of hepatitis C virus…”
Get full text

The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study by Curry, Michael P., Tam, Edward, Schneider, Caitlin, Abdelgelil, Noha, Hassanien, Tarek, Afdhal, Nezam H.

“…Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and…”
Get full text

Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis by McCarthy, Killian J., Motta-Calderon, Daniel, Estrada-Roman, Alisson, Cajiao, Karen M., Curry, Michael P., Bonder, Alan, Anagnostopoulos, Anne-Marie, Gavin, Michael

“…Recommendations on non-invasive imaging to assess pre-operative cardiac risk among liver transplant candidates vary amongst societal guidelines and individual…”
Get full text

Cytokine balance is restored as patient‐reported outcomes improve in patients recovering from chronic hepatitis C by Avila, Leyla, Weinstein, Ali A., Estep, J. Michael, Curry, Michael P., Golabi, Pegah, Escheik, Carey, Birerdinc, Aybike, Stepanova, Maria, Gerber, Lynn, Younossi, Zobair M.

“…Background & Aims Chronic hepatitis C (CHC) has a negative impact on patient‐reported outcomes (PROs). Although most CHC patients who achieve sustained…”
Get full text

The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population by Trivedi, Hirsh D., Suri, Jaspreet, Oh, Daheun, Schwartz, Jeffrey, Goyes, Daniela, Idriss, Rajab, Curry, Michael P., Lai, Michelle

“…Noninvasive liver assessment in type 2 diabetes (T2DM) in a primary care population identifies higher risk non-alcoholic fatty liver disease (NAFLD). We aimed…”
Get full text

Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA‐2B Score Among US Adults by Niezen, Sebastian, Tapper, Elliot B., Trivedi, Hirsh, Lai, Michelle, Curry, Michael P., Mukamal, Kenneth J., Jiang, Z. Gordon

“…Cirrhosis, a rising cause of death in the United States, has an extended preclinical phase characterized by progressive liver fibrosis. Despite the…”
Get full text

First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide by Pan, Calvin Q., Afdhal, Nezam H., Ankoma‐Sey, Victor, Bae, Ho, Curry, Michael P., Dieterich, Douglas, Frazier, Lynn, Frick, Andrew, Hann, Hie‐Won, Kim, W. Ray, Kwo, Paul, Milligan, Scott, Tong, Myron J., Reddy, K. Rajender

“…Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B…”
Get full text

Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients by Boone, M. Dustin, MD, Celi, Leo A., MD, MPH, Ho, Ben G., MS, Pencina, Michael, PhD, Curry, Michael P., MD, Lior, Yotam, BSc, Talmor, Daniel, MD, MPH, Novack, Victor, MD, PhD

“…Abstract Purpose Cirrhosis is a common condition that complicates the management of patients who require critical care. There is interest in identifying…”
Get full text

Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure by Wong, Florence, Pappas, Stephen Chris, Reddy, K. Rajender, Vargas, Hugo, Curry, Michael P., Sanyal, Arun, Jamil, Khurram

“…Summary Background Previous studies suggested increased mortality in patients with hepatorenal syndrome type 1 (HRS1) and advanced acute‐on‐chronic liver…”
Get full text